161 related articles for article (PubMed ID: 23073789)
1. A modified Latent Class Model assessment of human papillomavirus-based screening tests for cervical lesions in women with atypical glandular cells: a Gynecologic Oncology Group study.
Carter RL; Kang L; Darcy KM; Kauderer J; Liao SY; Rodgers WH; Walker JL; Lankes HA; Dunn ST; Stanbridge EJ
Cancer Causes Control; 2012 Dec; 23(12):2013-21. PubMed ID: 23073789
[TBL] [Abstract][Full Text] [Related]
2. Carbonic anhydrase IX and human papillomavirus as diagnostic biomarkers of cervical dysplasia/neoplasia in women with a cytologic diagnosis of atypical glandular cells: a Gynecologic Oncology Group study in United States.
Liao SY; Rodgers WH; Kauderer J; Bonfiglio TA; Walker JL; Darcy KM; Carter R; Hatae M; Levine L; Spirtos NM; Stanbridge EJ
Int J Cancer; 2009 Nov; 125(10):2434-40. PubMed ID: 19670419
[TBL] [Abstract][Full Text] [Related]
3. Sensitivity of high-risk HPV Hybrid Capture II (hrHPV HC2) test using SurePath(TM) specimens in the prediction of cervical high-grade squamous lesions.
Zhou F; Pulinthanathu R; Elgert P; Cangiarella J; Simsir A
Diagn Cytopathol; 2015 May; 43(5):381-7. PubMed ID: 25546355
[TBL] [Abstract][Full Text] [Related]
4. Cytology versus HPV testing for cervical cancer screening in the general population.
Koliopoulos G; Nyaga VN; Santesso N; Bryant A; Martin-Hirsch PP; Mustafa RA; Schünemann H; Paraskevaidis E; Arbyn M
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD008587. PubMed ID: 28796882
[TBL] [Abstract][Full Text] [Related]
5. Comparison of HPV-based assays with Papanicolaou smears for cervical cancer screening in Morelos State, Mexico.
Salmerón J; Lazcano-Ponce E; Lorincz A; Hernández M; Hernández P; Leyva A; Uribe M; Manzanares H; Antunez A; Carmona E; Ronnett BM; Sherman ME; Bishai D; Ferris D; Flores Y; Yunes E; Shah KV
Cancer Causes Control; 2003 Aug; 14(6):505-12. PubMed ID: 12948281
[TBL] [Abstract][Full Text] [Related]
6. Cross-reactivity profiles of hybrid capture II, cobas, and APTIMA human papillomavirus assays: split-sample study.
Preisler S; Rebolj M; Ejegod DM; Lynge E; Rygaard C; Bonde J
BMC Cancer; 2016 Jul; 16():510. PubMed ID: 27439470
[TBL] [Abstract][Full Text] [Related]
7. Can human papillomavirus DNA testing of self-collected vaginal samples compare with physician-collected cervical samples and cytology for cervical cancer screening in developing countries?
Bhatla N; Dar L; Patro AR; Kumar P; Kriplani A; Gulati A; Iyer VK; Mathur SR; Sreenivas V; Shah KV; Gravitt PE
Cancer Epidemiol; 2009 Dec; 33(6):446-50. PubMed ID: 19931499
[TBL] [Abstract][Full Text] [Related]
8. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Aptima and hybrid capture-2 HPV tests and Pap test in the referral population in Japan.
Kuroki H; Sakamoto J; Shibata T; Takakura M; Sasagawa T
J Med Virol; 2021 Aug; 93(8):5076-5083. PubMed ID: 33634473
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral.
Kulasingam SL; Hughes JP; Kiviat NB; Mao C; Weiss NS; Kuypers JM; Koutsky LA
JAMA; 2002 Oct; 288(14):1749-57. PubMed ID: 12365959
[TBL] [Abstract][Full Text] [Related]
11. Risk-adapted primary HPV cervical cancer screening project in Wolfsburg, Germany--experience over 3 years.
Luyten A; Scherbring S; Reinecke-Lüthge A; Braun BE; Pietralla M; Theiler K; Petry KU
J Clin Virol; 2009 Nov; 46 Suppl 3():S5-10. PubMed ID: 20129072
[TBL] [Abstract][Full Text] [Related]
12. Primary cervical cancer screening and triage using an mRNA human papillomavirus assay and visual inspection.
Nieves L; Enerson CL; Belinson S; Brainard J; Chiesa-Vottero A; Nagore N; Booth C; Pérez AG; Chávez-Avilés MN; Belinson J
Int J Gynecol Cancer; 2013 Mar; 23(3):513-8. PubMed ID: 23334437
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Onclarity Human Papillomavirus (HPV) Assay with Hybrid Capture II HPV DNA Assay for Detection of Cervical Intraepithelial Neoplasia Grade 2 and 3 Lesions.
Bottari F; Sideri M; Gulmini C; Igidbashian S; Tricca A; Casadio C; Carinelli S; Boveri S; Ejegod D; Bonde J; Sandri MT
J Clin Microbiol; 2015 Jul; 53(7):2109-14. PubMed ID: 25903574
[TBL] [Abstract][Full Text] [Related]
14. Atypical glandular cells in Pap tests: cytology-histology correlation and risk assessment with human papillopmavirus (HPV) testing.
Goetz LH; Evans HL; Armylagos D; Zhou H; Mody DR; Schwartz MR; Ge Y
J Am Soc Cytopathol; 2024; 13(3):227-232. PubMed ID: 38401997
[TBL] [Abstract][Full Text] [Related]
15. Screening for cervical cancer in high-risk populations: DNA pap test or Hybrid Capture II test alone?
Miranda Pereira SM; Castelo A; Makabe S; Utagawa ML; Di Loreto C; Sakamoto Maeda MY; Marques JA; Santoro CL; Filho AL; Das Dores GB
Int J Gynecol Pathol; 2006 Jan; 25(1):38-41. PubMed ID: 16306782
[TBL] [Abstract][Full Text] [Related]
16. Human papillomavirus testing improves the accuracy of colposcopy in detection of cervical intraepithelial neoplasia.
Monsonego J; Pintos J; Semaille C; Beumont M; Dachez R; Zerat L; Bianchi A; Franco E
Int J Gynecol Cancer; 2006; 16(2):591-8. PubMed ID: 16681731
[TBL] [Abstract][Full Text] [Related]
17. Value of conventional pap smear, liquid-based cytology, visual inspection and human papillomavirus testing as optional screening tools among latin american women <35 and > or =35 years of age: experience from the Latin American Screening Study.
Syrjänen K; Derchain S; Roteli-Martins C; Longatto-Filho A; Hammes LS; Sarian L;
Acta Cytol; 2008; 52(6):641-53. PubMed ID: 19068666
[TBL] [Abstract][Full Text] [Related]
18. Searching for an ideal cervical cancer screening model to reduce false-negative errors in a country with high prevalence of cervical cancer.
Song T; Seong SJ; Lee SK; Kim BR; Ju W; Kim KH; Nam K; Sim JC; Kim TJ
J Obstet Gynaecol; 2020 Feb; 40(2):240-246. PubMed ID: 31340702
[TBL] [Abstract][Full Text] [Related]
19. Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions.
Arbyn M; Roelens J; Simoens C; Buntinx F; Paraskevaidis E; Martin-Hirsch PP; Prendiville WJ
Cochrane Database Syst Rev; 2013 Mar; 2013(3):CD008054. PubMed ID: 23543559
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the AMPLICOR human papillomavirus test and the hybrid capture 2 assay for detection of high-risk human papillomavirus in women with abnormal PAP smear.
De Francesco MA; Gargiulo F; Schreiber C; Ciravolo G; Salinaro F; Manca N
J Virol Methods; 2008 Jan; 147(1):10-7. PubMed ID: 17854914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
